Shukra Pharmaceuticals Granted PAN India Distributorship by Wockhardt Limited

Shukra Pharmaceuticals Limited has been authorized by Wockhardt Limited, a leading global pharmaceutical company, to represent, distribute, and manage its products across all ESIC/ESIS Hospitals and Defence Hospitals / AFMSD / DGAFMS units across India. This non-exclusive authorization, valid till March 2026, empowers Shukra Pharmaceuticals Limited to quote products on behalf of Wockhardt Limited, collect order copies and raise invoices, and collect payments directly on behalf of Wockhardt Limited. The products include high-quality, advanced anti-infective formulations such as EMROK® (Levonadifloxacin) and MIQNAF® (Nafithromycin). This strategic distributorship marks a significant milestone in the growth journey of Shukra Pharmaceuticals Limited, strengthening its presence in institutional and government healthcare networks across India, enhancing revenue visibility and operational footprint, and creating long-term value for shareholders.